Patient demographics and baseline characteristics
| Variable . | MSKCC (n = 47) . | APML4 (n = 108) . | C9710 (n = 93) . |
|---|---|---|---|
| Age at diagnosis, y | |||
| <45 | 22 (47) | 57 (53) | 55 (59) |
| 45-60 | 12 (26) | 33 (31) | 26 (28) |
| >60 | 13 (28) | 18 (17) | 12 (13) |
| Sex | |||
| Female | 22 (47) | 54 (50) | 41 (44) |
| Male | 25 (53) | 54 (50) | 52 (56) |
| Median white blood cell count, 103/μL (IQR) | 2.3 (1, 4.7) | 2.4 (1.0, 7.9) | 3.6 (1.1, 16.4)* |
| White blood cell count > 10 (103/μL, high-risk) | 7 (15) | 24 (22) | 31 (33) |
| Median hemoglobin, g/dL (IQR) | 8.8 (6.9, 9.9) | 9.4 (8.1, 11.2) | 8.9 (8.1, 10.2)* |
| Median platelets, 103/μL (IQR) | 25 (15, 50) | 34 (19, 50) | 26 (15, 42)* |
| Coagulopathy present | 9 (21) | 16 (15) | N/A |
| ACA | 15 (32) | 34 (31) | 10 (30)† |
| Trisomy 8 | 7 | 18 | 5‡ |
| Deletion 9q | 3 | 4 | 0 |
| Trisomy 12q | 0 | 2 | 0 |
| +Xp | 1 | 1 | 0 |
| +6p | 0 | 2 | 0 |
| ider(17)(q10)t(15;17) | 0 | 0 | 2 |
| CK | 6 (13) | 11 (10) | 8 (9) |
| Treatment | |||
| ATRA+ATO | 27 (54) | 0 | 0 |
| ATRA+ATO+chemotherapy | 20 (40) | 108 (100) | 93 (100) |
| Variable . | MSKCC (n = 47) . | APML4 (n = 108) . | C9710 (n = 93) . |
|---|---|---|---|
| Age at diagnosis, y | |||
| <45 | 22 (47) | 57 (53) | 55 (59) |
| 45-60 | 12 (26) | 33 (31) | 26 (28) |
| >60 | 13 (28) | 18 (17) | 12 (13) |
| Sex | |||
| Female | 22 (47) | 54 (50) | 41 (44) |
| Male | 25 (53) | 54 (50) | 52 (56) |
| Median white blood cell count, 103/μL (IQR) | 2.3 (1, 4.7) | 2.4 (1.0, 7.9) | 3.6 (1.1, 16.4)* |
| White blood cell count > 10 (103/μL, high-risk) | 7 (15) | 24 (22) | 31 (33) |
| Median hemoglobin, g/dL (IQR) | 8.8 (6.9, 9.9) | 9.4 (8.1, 11.2) | 8.9 (8.1, 10.2)* |
| Median platelets, 103/μL (IQR) | 25 (15, 50) | 34 (19, 50) | 26 (15, 42)* |
| Coagulopathy present | 9 (21) | 16 (15) | N/A |
| ACA | 15 (32) | 34 (31) | 10 (30)† |
| Trisomy 8 | 7 | 18 | 5‡ |
| Deletion 9q | 3 | 4 | 0 |
| Trisomy 12q | 0 | 2 | 0 |
| +Xp | 1 | 1 | 0 |
| +6p | 0 | 2 | 0 |
| ider(17)(q10)t(15;17) | 0 | 0 | 2 |
| CK | 6 (13) | 11 (10) | 8 (9) |
| Treatment | |||
| ATRA+ATO | 27 (54) | 0 | 0 |
| ATRA+ATO+chemotherapy | 20 (40) | 108 (100) | 93 (100) |
IQR, interquartile range; N/A, not applicable.
Results are n (%) unless otherwise noted.
n = 92 patients with available data.
Detailed information on ACAs are available for 33 patients; percentage refers to those with the information available.
Includes 1 patient with partial trisomy of 8q and another who harbored +8 in 1 metaphase cell.